Are you Dr. Blocker?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1900 Randolph Rd
Ste 216
Charlotte, NC 28207Phone+1 704-316-5330Fax+1 704-384-5992
Summary
- Dr. Michael Blocker, MD is an infectious disease specialist in Charlotte, North Carolina. He is currently licensed to practice medicine in North Carolina. He is affiliated with Novant Health Presbyterian Medical Center and Novant Health Huntersville Medical Center.
Education & Training
- University of North Carolina HospitalsFellowship, Infectious Disease, 1997 - 2002
- University of North Carolina HospitalsResidency, Internal Medicine, 1994 - 1997
- University of Massachusetts Medical SchoolClass of 1994
Certifications & Licensure
- NC State Medical License 1996 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- 68 citationsEffectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: ...Deverick J. Anderson, Rebekah W. Moehring, David J. Weber, Sarah S. Lewis, Luke F. Chen
The Lancet. Infectious Diseases. 2018-06-04 - 25 citationsImplementation Lessons Learned From the Benefits of Enhanced Terminal Room (BETR) Disinfection Study: Process and Perceptions of Enhanced Disinfection With Ultraviolet...Deverick J. Anderson, Lauren P. Knelson, Rebekah W. Moehring, Sarah S. Lewis, David J. Weber
Infection Control and Hospital Epidemiology. 2018-01-14 - 210 citationsEnhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal ...Deverick J. Anderson, Luke F. Chen, David J. Weber, Rebekah W. Moehring, Sarah S. Lewis
Lancet. 2017-02-25